Interpretation of guidelines for the prevention and treatment of chronic hepatitis B (2022 edition)
10.3969/j.issn.1001-5256.2023.07.007
- VernacularTitle:《慢性乙型肝炎防治指南(2022年版)》解读
- Author:
Yandi XIE
1
;
Bo FENG
1
;
Huiying RAO
1
Author Information
1. Peking University People's Hospital, Peking University Hepatology Institute, Beijing 100044, China
- Publication Type:Guideline Interpretation
- Keywords:
Hepatitis B, Chronic;
Hepatitis B virus;
Practice Guidelines
- From:
Journal of Clinical Hepatology
2023;39(7):1553-1559
- CountryChina
- Language:Chinese
-
Abstract:
Guidelines for the prevention and treatment of chronic hepatitis B (2022 edition) are updated and revised based on the research advances in chronic hepatitis B virus infection in China and globally and the previous editions of the guidelines. This article introduces the updates in natural history and the noninvasive diagnosis and treatment of fibrosis. In particular, the guidelines further expand the indications for patients with chronic hepatitis B virus infection, clearly defines the selection of the population benefiting from interferon therapy, and strictly limits the standard of oral nucleos(t)ide analogues. Meanwhile, the guidelines also recommend more active treatment of patients with low-level viremia and children in the immune-tolerant phase. The new edition of the guidelines will provide an important basis for expanding the screening for hepatitis B virus infection, improving diagnostic rate, optimizing treatment regimens, and standardizing clinical management in China.
